Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Corona Remedies is an Ahmedabad-based branded-generics pharmaceutical company focused on the domestic formulations market, with strength in therapy areas such as women's health/gynaecology, cardio-metabolic care and pain management. Revenue comes from doctor-prescription-driven branded formulations sold through a field force across India. It listed on the exchanges recently (2025).
CORONA Remedies Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from CORONA Remedies Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 |
|---|---|
| EPS (basic, ₹) | 30.27 |
| Book value / share (₹) | 122.12 |
| Return on equity | 24.8% |
| Return on capital employed | 30.3% |
| Operating margin | 18.2% |
| Net margin | 13.2% |
| EBITDA | ₹293 Cr |
| Free cash flow | ₹55 Cr |
| Total debt | ₹143 Cr |
| Debt to equity | 0.19 |
| Interest coverage | 36.7 |
| Current ratio | 0.96 |
| Shares outstanding | 6,11,60,000 |
Open the full income statement, balance sheet and cash flow for CORONA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.